Grifols vs Sanofi (GRF vs SAN.PA)

Grifols (GRF) vs Sanofi (SAN.PA) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.

Grifols (GRF) and Sanofi (SAN.PA) compete in healthcare and pharma. Here are Grifols and Sanofi side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Grifols or Sanofi.

Grifols vs Sanofi: the figures

Grifols and Sanofi figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that Grifols or Sanofi figure is not available, and we never estimate it.

3 key differences between Grifols and Sanofi

1. Dividend: Sanofi yields 5.09% at today's price and Grifols yields 0.73%.
2. Debt: Grifols owes 5.0x its annual operating profit (EBITDA), while Sanofi owes 1.0x its EBITDA.
3. Valuation: Sanofi trades at 24.3x its annual earnings and Grifols at 15.8x; the market pays more for each dollar of Sanofi profit, usually because it expects more growth.

Grifols or Sanofi: which fits your profile

• If you want growth: Sanofi is growing faster today, so it fits better with investors who put business growth first, usually accepting a higher P/E and a bumpier ride.
• If you want income (dividends): Sanofi pays the higher dividend relative to its price.
• If you prefer caution: Sanofi has less debt relative to its profit, which usually gives more room in a bad year.
• If price is what matters most to you: Grifols trades on the lower P/E; check first whether that is an opportunity or a sign of a business that grows less.

Neither Grifols nor Sanofi wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.

How Grifols and Sanofi make money

Grifols (GRF)

Grifols collects plasma from donors at its network of centers, mostly in the US, and turns it into medicines. Its Biopharma division, the largest, sells immunoglobulins, albumin and other plasma proteins to hospitals; Diagnostic provides blood-screening tests for blood banks and labs; and Bio Supplies sells biological materials. Full Grifols analysis.

Sanofi (SAN.PA)

Sanofi is a drugmaker focused on its Biopharma business: specialty medicines for immunology, rare diseases and neurology, led by Dupixent, its top-selling product, plus flu, pediatric and booster vaccines. It sells to hospitals, pharmacies and health systems, with the US and Europe as its main markets. Full Sanofi analysis.

Frequently asked questions: Grifols vs Sanofi

Is Grifols or Sanofi the better stock?

Choosing between Grifols and Sanofi depends on what you are looking for. Sanofi is growing faster right now, and Grifols trades on the lower P/E. Fintols does not tell you whether to buy Grifols or Sanofi: it shows you the differences so you can decide.

Which pays a higher dividend, Grifols or Sanofi?

As of November 4, 2026, Sanofi yields 5.09% and Grifols yields 0.73%. Also check how much of their profit Grifols and Sanofi pay out: if it is more than they earn, it cannot last.

Which is more expensive, Grifols or Sanofi?

On P/E, Sanofi (24.3x) is more expensive than Grifols (15.8x) as of November 4, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.

Can I own both Grifols and Sanofi?

Yes. Many people spread their money across several companies, such as Grifols and Sanofi, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Grifols or Sanofi.

More comparisons with Grifols or Sanofi

• Grifols vs Laboratorios Rovi
• Bayer vs Grifols
• argenx vs Grifols
• Bayer vs Sanofi

More companies like Grifols and Sanofi: healthcare and pharma stocks. Educational content about Grifols and Sanofi, not investment advice.